Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Novel Therapy
Sort By
Newest First
1 / 1
Cancer Research
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-To-Treat Cancers
Inceptor Bio
PR-M06-21-018
Jun 14, 2021
Cell Line Development
Rising Demand for Novel Cancer Treatment Approaches to Propel Cell Line Development Market through 2024
Global Market Insights
PAO-M11-19-NI-007
Nov 20, 2019
Tumor Microenvironment
Focusing on the Tumor Microenvironment Leads to Novel Drug Targets
Shaan C. Gandhi, M.D., Ph.D.
Pyxis Oncology
PAP-Q3-19-CL-023
Oct 28, 2019
Novel Therapies
Q: What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?
Pharma's Almanac
PAP-Q2-2019-NI-007
May 23, 2019
Novel Therapy
Novel Combination Therapy Promotes Wound Healing
Albert Einstein College of Medicine
PR-M10-18-NI-096
Oct 29, 2018
Drug Development
First Light Biosciences Develops a Novel Method for Rapidly Determining Effective Antibiotics for Treating Infections
First Light Biosciences:
PR-M10-18-NI-010
Oct 02, 2018
Artificial Intelligence
AI-Guided Cancer Therapy Platform from SRI International Identifies Novel Molecular Targets for Aggressive Form of Breast Cancer
SRI Biosciences
PR-M04-18-NI-71
Apr 20, 2018
Immuno-Oncology
FIMECS, Inc. Concludes Licensing Agreement with Takeda to Develop Novel Immuno-Oncology Therapies
FIMECS, Inc.
PR-M04-18-NI-44
Apr 13, 2018
Fast Track
Biostage awarded SBIR Fast-Track grant to develop Cellspan™ Esophageal Implant (CEI) as a novel treatment for esophageal atresia in pediatric patients
Biostage, Inc.
PR-M04-18-NI-002-4473
Apr 02, 2018
Drug Development
Celgene, Vividion Therapeutics Collaborate on Novel Protein Drugs
Guy Tiene
Nice Insight
PAO-M03-18-NI-005
Mar 08, 2018
Clinical Trials
Rexgenero Treats First Patient in its Phase III Programme with Lead Product REX-001, a Novel Cell Therapy for the Treatment of Critical Limb Ischemia (CLI)
Rexgenero
PR-M01-18-NI-093
Jan 30, 2018
CFDA
China FDA Publishes Guidance for Priority Review
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M01-18-NI-013
Jan 09, 2018
Strategic Partnership
Dicerna and Boehringer Ingelheim Ink Deal to Develop Treatments for Chronic Liver Diseases
Nice Insight
PAO-M11-17-NI-022
Nov 14, 2017
1 / 1
